000			03150nam a2200409 i 4500
999			_c112655 _d112655
001			112655
003			ES-MaUEC
005			20230215121832.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			181127s2019 gw a o |||| 0|eng d
020			_a9783319935300
024	7		_a10.1007/978-3-319-93530-0 _2doi
040			_bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC270 _b2019 EB
245	0	0	_aImmunotherapy of Sarcoma _cedited by Sandra P. D'Angelo, Seth M. Pollack
264		1	_aCham _bSpringer International Publishing _c2019
300			_a1 recurso en línea (VII, 152 páginas) _b10 ilustraciones, 7 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aMedicine (Springer-11650)
505	0		_aPart 1 The Immune Sarcoma Microenvironment -- 1 MDSC, Macrophage and CD47 -- 2 IDO and other inhibitory markers -- 3 Regulatory T cells -- 4 Radiation and sarcoma immunotherapy -- Part 2 Sarcoma Immunotherapeutics -- 5 Oncolytic Virus therapy -- 6 Vaccines -- 7 Immune Checkpoint Blockers -- 8 Adoptive T cell therapy.
520	3		_aThis book describes recent progress in the development of immunotherapies for advanced sarcoma, paying special attention to the potential role of manipulations of the sarcoma tumor immune microenvironment in achieving durable remissions. Readers will find a thorough overview of the state of the art in tumor immunology and immunotherapy as they relate to sarcoma. Among the topics addressed are advances in vaccine therapy; the value of adoptive transfer of cytokine-induced natural killer cells; the development of adoptive T cell strategies; and the scope for use of checkpoint inhibitors in patients with sarcoma, mirroring the tremendous breakthroughs made in other malignancies. Detailed information is provided on laboratory and clinical research, with analysis of outcomes of recent trials and identification of key challenges. There is every reason to believe that more effective and less toxic therapies for metastatic sarcoma can be attained by deepening our understanding of cancer immunology and building on the advances in immunotherapy for other solid tumors. In this context, Immunotherapy of Sarcoma will be of high interest for all medical oncologists responsible for the treatment of sarcoma patients.
988			_aSpringer_Medicine_2019
650		7	_aCáncer _2embne _9182544 _xDiagnóstico
650		7	_aInmunología _2embne _9138330
700	1		_aD'Angelo, Sandra P. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aPollack, Seth M. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _9106996
776	0	8	_iPrinted edition: _z9783319935294
776	0	8	_iPrinted edition: _z9783319935317
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-93530-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_dz _b02/2023 _eb _zSI